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Abstract
Background: Laboratory testing is the single highest-volume medical activity and drives clinical decision-making across
medicine. However, the overall landscape of inappropriate testing, which is thought to be dominated by repeat testing, is
unclear. Systematic differences in initial vs. repeat testing, measurement criteria, and other factors would suggest new
priorities for improving laboratory testing.
Methods: A multi-database systematic review was performed on published studies from 1997–2012 using strict inclusion
and exclusion criteria. Over- vs. underutilization, initial vs. repeat testing, low- vs. high-volume testing, subjective vs.
objective appropriateness criteria, and restrictive vs. permissive appropriateness criteria, among other factors, were
assessed.
Results: Overall mean rates of over- and underutilization were 20.6% (95% CI 16.2–24.9%) and 44.8% (95% CI 33.8–55.8%).
Overutilization during initial testing (43.9%; 95% CI 35.4–52.5%) was six times higher than during repeat testing (7.4%; 95%
CI 2.5–12.3%; P for stratum difference ,0.001). Overutilization of low-volume tests (32.2%; 95% CI 25.0–39.4%) was three
times that of high-volume tests (10.2%; 95% CI 2.6–17.7%; P,0.001). Overutilization measured according to restrictive
criteria (44.2%; 95% CI 36.8–51.6%) was three times higher than for permissive criteria (12.0%; 95% CI 8.0–16.0%; P,0.001).
Overutilization measured using subjective criteria (29.0%; 95% CI 21.9–36.1%) was nearly twice as high as for objective
criteria (16.1%; 95% CI 11.0–21.2%; P=0.004). Together, these factors explained over half (54%) of the overall variability in
overutilization. There were no statistically significant differences between studies from the United States vs. elsewhere
(P=0.38) or among chemistry, hematology, microbiology, and molecular tests (P=0.05–0.65) and no robust statistically
significant trends over time.
Conclusions: The landscape of overutilization varies systematically by clinical setting (initial vs. repeat), test volume, and
measurement criteria. Underutilization is also widespread, but understudied. Expanding the current focus on reducing
repeat testing to include ordering the right test during initial evaluation may lead to fewer errors and better care.
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Introduction
Laboratory testing is an integral part of modern medicine.
Testing figures prominently across specialties and in multiple
medical contexts, including outpatient screening (e.g. cholesterol
for heart disease, hemoglobin A1c for diabetes mellitus), inpatient
diagnosis and management, and disease monitoring (e.g. tumor
markers for cancer). As a result, testing is the single highest-volume
medical activity, with an estimated 4–5 billion tests performed in
the United States each year [1]. Testing is often the principal basis
for more costly downstream care. It also features prominently in
pay-for-performance guidelines and compliance standards, mak-
ing it a potential target for cost savings under global payment plans
[2–5]. However, the prevalence of inappropriate testing is
unknown.
Inappropriate testing takes several forms. Overutilization or over-
ordering refers to tests that are ordered but not indicated, while
underutilization refers to tests indicated but not ordered. There is
inappropriate initial testing, for example, during the initial
evaluation of a patient or in response to new signs or symptoms,
and inappropriate repeat testing. There are also different kinds of
inappropriateness criteria. Objective criteria are clearly defined and
investigator-independent, while subjective criteria depend on expert
review. Restrictive criteria require there to be a clear indication for
ordering a test, while permissive criteria require only that there be
no contraindication. Restrictive and permissive criteria – terms
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and ‘‘innocent-until-proven-guilty’’ approaches to inappropriate
testing.
Whatever the context or criteria, inappropriate testing can
cause harm and lead to medical errors. Overutilization can result
in unnecessary blood draws and other sample-collection proce-
dures [6,7]. It also increases the likelihood of false-positive results,
which can lead to incorrect diagnoses, increased costs, and adverse
outcomes due to unwarranted additional intervention [8,9].
Underutilization can result in morbidity due to delayed or missed
diagnoses and in downstream overutilization. Over- and under-
utilization can both lead to longer hospital stays and contribute to
legal liability. A recent review of malpractice claims in an
outpatient setting found failures to order or correctly interpret
laboratory tests in one in every eight claims, often with multiple
occurrences per claim [10]; a similar study from an emergency-
room setting found a rate of one in seven [11].
Studies of specific tests and clinical scenarios suggest that
inappropriate laboratory testing is a serious problem throughout
medicine [12–20]. However, there are also studies that have found
rates of inappropriate testing to be low [21–28]. Recent trends in
medicine can be marshaled to support either view. On the one
hand, evidence-based practice and clinical decision support (CDS)
encourage appropriate testing. On the other, defensive medicine
and panel-based ordering encourage overutilization [29]. The only
previous systematic review, published 15 years ago, can likewise be
interpreted variably: it found rates of inappropriate testing that
ranged from 4% to 95% [27]. However, it covered only through
September 1997 and thus preceded major recent developments in
health-care quality [30–34]. To chart the landscape of inappro-
priate testing, we performed a systematic review of audits on the
appropriateness of laboratory testing over the past 15 years in
order to estimate the overall prevalence of inappropriate
laboratory testing and compared over- vs. underutilization,
inappropriate initial vs. repeat testing, and different types of
criteria.
Materials and Methods
Methodology
We conducted our analysis according to MOOSE and
PRISMA guidelines (see Checklist S1 and Checklist S2 in File S1)
[35]. No prior protocol existed for our study. The context was
global.
Data Sources and Searches
We searched Medline for studies published between October
1997 and January 2012 by crossing relevant medical subject
headings (MeSH terms) with subheadings and text words (e.g.
‘‘utilization,’’ ‘‘laboratory test (s)’’). Only citations on human
subjects were included. For completeness, we repeated the search
without subheadings and combined the results of these two
searches. We similarly searched the Embase (Elsevier), BIOSIS
(Thomson Reuters), CINAHL (EBSCO), and Cochrane databas-
es. See File S1 for details.
Study Selection
For each citation, two investigators [M.Z. and R.A.] indepen-
dently screened the title and abstract for potential relevance. The
results were combined. For citations considered potentially
relevant, we evaluated the study in depth according to the
following specific inclusion and exclusion criteria. Studies were
included if (i) they specified valid criteria for appropriateness of
laboratory testing as well as explicit reference to previous literature
and/or published guidelines, (ii) the criteria were based on a
population that was independent of the study, and (iii) they
implemented these criteria in an audit. Studies were excluded if
they (i) covered only radiographic imaging or anatomic/surgical
pathology testing, (ii) covered only laboratory quality control issues
but not the appropriateness of testing, or (iii) had no version
available completely in English. To reduce bias, two investigators
[J.T. and R.A.] independently evaluated each included study for
the validity and appropriateness criteria used in the study, with
disagreements resolved by discussion. See File S1 for details on
validity, appropriateness, and language criteria. For completeness,
we further evaluated all cited literature (manually) and citing
literature (using Thomson ISI’s Web of Science; Thomson
Reuters, NY) for all studies that met selection criteria. For studies
identified in this way, we again evaluated all citing and cited
literature to identify additional studies. We repeated this step
iteratively until no additional studies were found that met selection
criteria (Fig. 1).
Data Extraction and Quality Assessment
For each included study, two investigators [M.Z. and R.A.]
abstracted the year of publication, country, and name (s) of test (s)
studied. We annotated tests as chemistry, hematology, microbiol-
ogy, or molecular. We also abstracted (where available) or
calculated (where not) the number of tests ordered but not
indicated (overutilization) or indicated but not ordered (underuti-
lization) according to the study’s criteria; the total number of tests
ordered; and the percent overutilization (the number of tests
ordered but not indicated divided by the total number of tests
ordered 6100) or underutilization (the number indicated but not
ordered divided by the total number indicated 6100). Where a
study reported results from multiple tests, all tests were considered
for inclusion, with each test having its own measurement where
possible (its own percent over- or underutilization and its own total
number of tests ordered). Where rate (or numerator and/or
denominator) or criteria were not available for a test from a given
study, that test was excluded. In studies of the pre- vs. post-
intervention type, only pre-intervention data were considered,
since pre-intervention rates of utilization more likely reflect the
landscape of appropriateness across study sites, while post-
intervention rates apply only to the site at which the intervention
was carried out.
For measures of overutilization, we determined whether the
inappropriateness criteria were objective or subjective; restrictive,
permissive, or both; and whether they involved initial testing,
repeat testing, or both. Test volume (low, medium, or high) was
determined as described in the File S1.
Data Synthesis and Analysis
The percent inappropriate testing (dichotomous data) described
different tests and clinical scenarios. Therefore, within the set of
study measures for overutilization, and separately for underutili-
zation, we combined study measures using random-effects models
and performed meta-regressions. Over- and underutilization data
were not combined, since they are calculated as percentages of
different denominators (total tests ordered vs. total tests appropri-
ate). Mean rates (proportions) and 95% confidence intervals (CIs),
binomial variance, and R-squared (R
2) were calculated for all
groups and subgroups, both separately and controlling for each
other (see File S1). We followed the standard practice of adjusting
numerators of zero to 0.5 to allow inclusion. We performed
subgroup analysis on study measures of over- and underutilization,
although the number of study measures of underutilization was too
small to draw conclusions about subgroups. Sensitivity analyses
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removing extreme-value studies as appropriate and repeating
regressions. We also tested for trends over time (see File S1). All
statistical analyses were performed using Stata (version 11.2;
StataCorp LP, College Station, Texas, USA) and Microsoft Excel
for Mac 2011 (version 14.1.4, Microsoft Corp., Redmond,
Washington, USA).
Results
Literature search
Our initial literature search identified 34,009 citations. A two-
investigator independent manual review yielded 493 studies that
were potentially relevant. Applying selection criteria, we excluded
452 because inappropriateness was not defined or calculated (the
most common reason for exclusion); the study was a review,
survey, case study, or commentary; data were inconsistent; the
study was not available in English; and/or the study was a
duplicate of another study in the set. Most of the studies for which
inappropriateness was not calculated studied the number of tests
ordered (total utilization) but not the appropriateness of the orders;
the rest reported the number of patients, patient encounters, or
providers who encountered or experienced inappropriate testing
but not the number of tests.
Another four of the 493 studies (0.8%) were not evaluated
because they could not be found despite a thorough search by a
professional research librarian [J.W.]. These exclusions left 37
studies. We then applied our eligibility criteria to all studies that
cited or were cited by these studies, and repeated this step
iteratively until no additional studies were discovered. This
additional search resulted in five additional studies, for a total of
42 studies (Figure 1). These 42 reflect agreement among the
investigators on all but three studies (42/45; 93% agreement rate);
after discussion, these three were excluded.
Study characteristics
Thirty-eight studies investigated overutilization [15,17–
20,22,23,25,26,28,36–63]; eight investigated underutilization
[25,45,48,57,64–67]; four investigated both [25,45,48,57]. Thirty-
one studies used objective criteria for measuring appropriateness
[17,18,22,23,26,28,37,38,40–45,47–49,52,54–59,61–67] while 11
used subjective criteria [15,19,20,25,36,39,46,50,51,53,60].Twenty
studies investigated more than one test. Ten studies analyzed the
same data using multiple criteria, resulting in multiple study
measures for the same laboratory test (s) for each of these studies
[23,25,38,45,57,64–67]. Of the 27 studies that investigated
overutilization using objective criteria [17,18,22,23,26,28,37,38,
40–45,47–49,52,54–59,61–63], 12 used repeat testing as part of
their criteria [22,23,26,28,38,40,41,44,45,48,52,59] and all but two
of these investigated repeat testing exclusively [48,59]; 18 used non-
repeat-based criteria [17,18,37,38,42,43,47–49,54–59,61–63].
Sixteen studies used only restrictive criteria [15,18–20,25,
Figure 1. Literature Search Strategy and Results, 1997–2012. The indicated databases were searched as described in the main text and
File S1. Number of studies indicated. *Results from searching with and without subheadings.
doi:10.1371/journal.pone.0078962.g001
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[17,22,23,26,28,39–41,43,44,50,52,55,59,60,62,64–66], and seven
used both [45,46,54,56–58,61] (see Table S1 in File S1). Begg’s test
revealed no obvious publication bias (see File S1).
Study measures and test coverage
The 42 studies contributed 132 study measures of inappropri-
ateness based on a total of 1,605,095 tests ordered, for an average
of 38,217 orders/measure and 3.1 measures/study. Only six study
measures (involving prostate-specific antigen [PSA], thyroid
studies, and pre-operative testing) were considered screening tests.
Study measures covered 46 of the 50 most frequently ordered
laboratory tests at the Beth Israel Deaconess Medical Center (see
File S1) and essentially all common tests and panels. These
included tests of the basic metabolic panel (e.g. sodium, glucose)
[18,22,23,25,28,39,50,57,60,62] and complete blood count (he-
moglobin, white blood cell count) [18,22,25,39,50,57,60]; com-
mon disease monitoring tests (cholesterol, hemoglobin A1c)
[45,50]; tests of cardiac (creatine kinase) [18,50], liver (transam-
inases, alkaline phosphatase) [18,23,25,39,50,54,62,63,65], thy-
roid (thyroxine, thyroid stimulating hormone) [64], and kidney
function (blood urea nitrogen, creatinine) [18,22,23,25,39,
50,57,60,62], tests for anemia (iron, ferritin, B12, serum folate)
[39,40], coagulopathy (prothrombin time, partial thromboplastin
time [PTT], protein C, protein S, D-dimer) [18,39,42,50,
55,57,61,66], and inflammation and autoimmunity (C-reactive
protein, erythrocyte sedimentation rate, autoimmune antibodies,
amylase, lipase) [15,18,19,41,44,47,50,59,62]; tests for infection
(human immunodeficiency virus Western blot, hepatitis B surface
antigen, Venereal Disease Research Laboratory syphilis testing,
malarial smear, stool and urine microscopy) [17,22,25,52,54,58];
tests for monitoring therapeutic drugs (digoxin, anti-epileptics)
[20,22,36–38,48,51,53]; cancer markers (carcinoembryonic anti-
gen) [43,44,46,56]; and molecular tests (HFE gene mutation).[26]
In all, there were 104 chemistry (31 studies) [15,18–
20,22,23,25,36–39,41,43–46,48–51,53,56,57,59,60,62–65,67] 24
hematology (13 studies)
[18,22,25,39,40,42,47,50,55,57,60,61,66] 10 microbiology (six
studies) [17,22,25,52,54,58]; and three molecular test study
measures (one study) [26].
Overall rates of inappropriate laboratory testing, 1997–
2012
The overall mean rate of inappropriate overutilization was
20.6% (95% CI 16.2–24.9%; n=114). The overall mean rate of
inappropriate underutilization was higher, at 44.8%, but was
based on fewer total study measures (95% CI 33.8–55.8%; n=18;
P for difference ,0.001; Table 1 and Figure 2a).
Overutilization: initial vs. repeat testing
Among study measures of overutilization, the mean rate of
inappropriate initial testing – for example, ordering PTT to dose
warfarin or low molecular-weight heparin [55] – was 43.9%
(95% CI 35.4–52.5%; n=18). The mean rate of inappropriate
repeat testing – for example a fourth daily set of serum
electrolytes when results from the previous three were all within
the reference interval [23] – was 7.4% (95% CI 2.5–12.3%;
n=55), a six-fold difference (Table 1 and Figure 2b; P for
stratum difference ,0.001). Forty-one study measures included
both initial and repeat-testing criteria. The mean rate for these
(28.0%; 95% CI 22.2–33.8%) fell in between rates for initial and
repeat testing.
Overutilization: effect of criteria type
The mean rate for study measures that used restrictive criteria
(44.2%; 95% CI 36.8–51.6%; n=26) was five times the rate for
those that used permissive criteria (e.g. repeat PSAs within
12 weeks of each other [44]; 12.0%; 95% CI 8.0–16.0%; n=82;
P,0.001; Table 1 and Figure 2c). In addition, the mean rate for
study measures that used subjective criteria (29.0%; 95% CI
21.9–36.1%; n=40) was significantly higher than for those that
used objective criteria (16.1%; 95% CI 11.0–21.2%; n=74;
P=0.004; Table 1 and Figure 2d). The difference between
restrictive and permissive criteria was still significant when
controlling for whether study measures were objective vs.
subjective (P,0.001) and vice versa (P=0.045), and also when
controlling for inappropriate initial vs. repeat testing (P,0.001)
and vice versa (P,0.001).
Overutilization: effect of test volume
The mean rate of inappropriate testing for low-volume tests
(e.g. carbamazepine levels, carcinoembryonic antigen; 32.2%;
95% CI 25.0–39.4%; n=36) was significantly higher than for
medium- (e.g. albumin, alkaline phosphatase; 19.8%; 95% CI
12.2–27.5%; n=31) or high-volume tests (e.g. those of the basic
metabolic panel; 10.2%; 95% CI 2.6–17.7%; n=32; P,0.001;
Table 1). Although several study measures of repeat testing were
of high-volume tests [23,28], the difference between initial and
repeat testing was still significant when controlling for test
volume (P,0.001) and vice versa (P,0.001).
Figure 2. Histograms of Study Measures of Inappropriate
Laboratory Test Utilization, 1997–2012. Cumulative distributions
of A, overutilization vs. underutilization (P,0.001); B, overutilization,
initial vs. repeat testing (P,0.001); C, overutilization, restrictive vs.
permissive criteria (P,0.001); and D, overutilization, subjective vs.
objective criteria (P=0.027). Each curve can be interpreted as the
probability (y-axis) that a test was at least as inappropriate as indicated
on the x-axis. For example in panel B, a third of study measures of initial
testing (open arrowhead, y-axis) found at least 60% inappropriateness
(closed arrowhead, x-axis).
doi:10.1371/journal.pone.0078962.g002
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Despite the diversity of tests and clinical settings, over half of the
overall variability in overutilization was explained by just three
factors: timing (initial vs. repeat testing), type of criteria, and test
volume (cumulative R
2=54%).
Overutilization and underutilization: trends over time
We found no meaningful statistically significant changes in
mean rates of inappropriate over- or underutilization between
1997 and 2012 that were robust to sensitivity analysis (see
Figure S1 in File S1).
Discussion
Overuse, underuse, and misuse of health-care resources is
estimated at 30 percent [34,68,69]. Here we present systematic
evidence that laboratory testing is no exception and describe the
complex landscape of errors in this highest-volume medical
activity.
Underutilization vs. overutilization
On average, the available evidence suggests that underutiliza-
tion is more prevalent than overutilization (44.8% vs. 20.6%). This
was despite there being only one-fifth the number of studies on
underutilization as overutilization during the study period. We do
not think the relative lack of studies of underutilization reflects bias
in our search methodology, which evaluated over 34,000 studies
and succeeded in identifying studies from the previous systematic
review [27]. Instead we think it reflects a general emphasis on
overutilization relative to underutilization across health care
during our study period [34,68,69], despite the potential causal
relationship between overutilization and upstream underutiliza-
tion. The relatively small number of study measures of underuti-
lization precluded subgroup analysis and suggests cautious
interpretation. However, with a lower 95% confidence bound of
33.8% average underutilization, our results suggest that underuti-
lization in laboratory testing may be a sizeable, underappreciated,
and understudied problem that merits further research.
Initial vs. repeat overutilization
‘‘Inappropriate’’ and ‘‘overutilization’’ are sometimes used
narrowly as synonyms for inappropriate repeat testing – for
example, repeat daily electrolytes on inpatients regardless of
clinical status (2.5–5.7% inappropriate in one study) [23].
However, our analysis shows that on average, initial testing has
a much higher rate of overutilization (43.9% vs. 7.4%) – for
example ordering D-dimer despite high pre-test probability for
pulmonary embolism (62% of D-dimer orders) [42]. This
distinction is robust and remains statistically significant even after
controlling for potentially confounding variables such as test
volume. There are documented methods for changing test-
ordering behavior. These include health information technology-
based CDS as well as educational interventions. Our results
support focusing such methods on improving initial test ordering.
Test volume
We find that low-volume tests are ordered inappropriately at a
higher rate than medium- or high-volume tests. This may result
Table 1. Rates of inappropriate laboratory testing, 1997-2012.
Characteristic Error rate (95% CI) Difference (95% CI) n Stratum differences
Variability
explained
Subgroup
Overutilization 20.6 (16.2, 24.9) (reference) 114 P,0.001 11%
Underutilization 44.8 (33.8, 55.8) 24.2 (12.5, 36.0) 18
Overutilization
Initial testing 43.9 (35.4, 52.5) (reference) 18 P,0.001 38%
Repeat testing 7.4 (2.5, 12.3) 236.5 (246.4, 226.7) 55
Both 28.0 (22.2, 33.8) 215.9 (25.6, 226.3) 41
Restrictive criteria 44.2 (36.8, 51.6) (reference) 26 P,0.001 36%
Permissive criteria 12.0 (8.0, 16.0) 232.2 (240.6, 223.8) 82
Subjective criteria 29.0 (21.9, 36.1) (reference) 40 P=0.004 6%
Objective criteria 16.1 (11.0, 21.2) 212.9 (221.6, 4.1) 74
Low volume 32.2 (25.0, 39.4) (reference) 36 P,0.001 11%
Medium volume 19.8 (12.2, 27.5) 212.4 (222.9, 21.8) 31
High volume 10.2 (2.6, 17.7) 222.0 (232.5, 211.6) 32
Chemistry tests 19.1 (14.3, 24.0) (reference) 86 NA
a 2%
Hematology tests 33.3 (20.2, 46.3) 14.1 (0.1, 28.1) 12
Microbiology tests 23.1 (6.1, 40.2) 4.0 (213.7, 21.7) 7
Molecular tests 1.5 (0, 27.4) 217.6 (244.0, 8.8) 3
United States 25.0 (14.0, 36.1) (reference) 17 P=0.38 ,1%
Non-US 19.7 (15.1, 24.4) 25.3 (217.3, 6.7) 97
Subgroup Summary Statistics.
aP for stratum differences is meaningful only when there is a natural ordering for categories. P for difference of means: chemistry vs. hematology, P=0.05; chemistry vs.
microbiology, P=0.65; chemistry vs. molecular, P=0.17; hematology vs. microbiology, P=0.43; hematology vs. molecular, P=0.07; microbiology vs. molecular, P=0.19.
doi:10.1371/journal.pone.0078962.t001
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among physicians. However, when taking into account the total
number of inappropriate tests, on a per-order (as opposed to per-
analyte) basis, high-volume tests likely represent the bigger target
for improvement.
Permissive vs. restrictive criteria
Ideally no medical decision is made without a reason. Decisions
to perform surgery, order imaging, or prescribe medication are
considered inappropriate absent specific indications. This ‘‘guilty-
until-proven-innocent’’ approach to decision-making is exercising
what we call restrictive criteria. The opposite, ‘‘innocent until
proven guilty,’’ reflects a less skeptical, ‘‘why-not?’’ attitude in
which decisions are considered appropriate absent specific
contraindications. This is decision-making according to permissive
criteria. Our results support the view that decision-making in
laboratory testing is too often permissive. By definition, permissive
criteria underestimate overall inappropriateness. Restrictive crite-
ria are more explicit about indications and therefore more
thorough. For this reason we believe restrictive criteria provide
the better measure of inappropriate ordering. Study measures
based on restrictive criteria show a mean rate of 44.2%
inappropriate overutilization, significantly higher than the mean
rate for permissive criteria (12.0%) even after controlling for the
fact that inappropriate repeat testing is an example of permissive
criteria (because the test is considered appropriate unless
inappropriately repeated). For a clearer picture of overutilization,
future studies should favor restrictive criteria.
Subjective vs. objective criteria
Generally, studies that use objective criteria are considered
more dependable than those that use subjective criteria. However,
that the mean rate of inappropriate overutilization for studies that
used subjective criteria (29.0%) was nearly double that for
objective criteria (16.1%) merits explanation. It is possible that
this difference reflects investigator bias: investigators subjectively
believe inappropriate testing is more widespread than it objectively
is. However, we favor an alternative explanation: objective criteria
for laboratory testing are generally incomplete, while subjective
criteria – expert review – judge cases against additional rules and
clinical nuances that are often missing from the objective criteria
used. We believe the way forward is not to abandon objective
criteria but to make objective criteria more complete by working
toward defining comprehensive sets of objective indications for the
appropriate use of each laboratory test, even as these indications
evolve over time.
Limitations
One could argue that despite an in-depth literature search and
coverage of 46 of the 50 most common tests, the total number of
studies and study measures reviewed here is small relative to the
total number of tests and clinical scenarios encountered in clinical
practice. In part this arises from our decision to include studies of
utilization only if they explicitly addressed the appropriateness of
the tests. This restriction was necessary to avoid confusing the
number of tests being ordered (utilization) with the appropriate-
ness of those tests (e.g. to distinguish low overutilization from high
underutilization). In part it is simply because tests and scenarios
outnumber studies published during the study period. Unfortu-
nately, this imbalance precludes subgroup analysis of underutili-
zation, analysis of the appropriateness of specific tests over time or
according to competing guidelines, or differences between
inpatient and outpatient settings, small and large hospitals, implicit
review and pure subjective review, trainees and experienced
practitioners, and generalists and specialists. These are topics for
future study. One could also ask whether pooling study measures is
desirable given the heterogeneity of tests and testing indications.
However, the limited pooling we performed for our subgroup
analyses revealed broad, consistent, clinically valuable patterns in
laboratory overutilization, and these patterns remained statistically
robust when controlling for potential biases of pooling. The
availability of more data will allow other techniques and further
insights.
One could argue that we cannot completely exclude potential
publication bias or selective reporting of results by the studies we
included. Indeed, in many of these studies, investigators reported a
suspicion of inappropriate testing as part of their motivation.
Consequently, we cannot say for sure whether the studies covered
in our analysis document the worst offenders or the tip of an
‘‘iceberg of errors’’ [12]. However, we note rough agreement (for
overutilization) among rates of inappropriate initial testing,
inappropriate testing according to restrictive criteria, and inap-
propriate testing according to subjective criteria, subgroups with
no or relatively little pairwise overlap. Also, Begg’s test showed no
obvious bias. These observations suggest that our results are likely
representative of practice across medicine.
Finally, one could ask how well ‘‘appropriateness’’ approximates
the best possible care. All rules have exceptions. Inevitably in
medicine situations will arise in which the best decision will seem
to run counter to available appropriateness criteria. Also, different
appropriateness criteria may contradict each other. Thus, at least
by conventional measures, zero inappropriateness is an unrealistic,
probably undesirable goal. The included studies do not allow for
quantitative definitions of what a realistic or desirable goal might
be. However, our review of their appropriateness criteria supports
the conclusion that over- and underutilization are both more
common than they should be.
Conclusions
Inappropriate testing is not just unnecessary repeat blood draws.
Our work reveals a landscape of inappropriate testing where rates
vary systematically according to setting, test volume, and criteria
in ways that can inform clinical practice and future research. For
example, focusing on ordering the right test during initial
evaluation, as opposed to reducing repeat testing, may have the
greater impact on reducing errors and improving care.
What about reducing cost? Laboratory testing itself accounts for
only a tiny fraction (,3–5%) of healthcare spending [2]. The true
costs associated with testing include the costs or savings of the
downstream activities that testing leads to or prevents. The costs of
these downstream activities – prescriptions, imaging, surgeries,
hospital stays – dwarf the cost laboratory testing [2,70]. Economic
models of how testing influences these activities would be useful.
Meanwhile, insofar as testing is considered appropriate only if it
supports the standard of care, which in turn is defined according to
patient outcomes, improving laboratory utilization should lead to
more cost-effective care, regardless of whether more appropriate
utilization leads to fractionally lower, or even fractionally higher,
testing costs. We suggest further study of over- and underutiliza-
tion in tandem, and in the context of downstream costs and
outcomes, to learn how best to improve the efficiency and
effectiveness of care.
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